Treatment of metabolic syndrome in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 29, Issue SUPPL. 2, 2009, Pages

  Li, Philip Kam Tao ^a   Kwan, Bonnie Ching Ha ^a   Ko, Gary Tin Choi ^a   Chow, Kai Ming ^a   Leung, Chi Bon ^a   Szeto, Cheuk Chun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Metabolic syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINO ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIOBESITY AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICODEXTRIN; INSULIN; PERITONEAL DIALYSIS FLUID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; ROSIGLITAZONE;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; DIET RESTRICTION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DYSLIPIDEMIA; EXERCISE; GASTRIC BANDING; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INFLAMMATION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOMES RESEARCH; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; WEIGHT GAIN; CHRONIC KIDNEY FAILURE; HONG KONG; KINESIOTHERAPY; LIFESTYLE; METHODOLOGY; PATIENT EDUCATION; REVIEW; RISK FACTOR;

EXERCISE THERAPY; HONG KONG; HUMANS; KIDNEY FAILURE, CHRONIC; LIFE STYLE; METABOLIC SYNDROME X; PATIENT EDUCATION AS TOPIC; PERITONEAL DIALYSIS; PREVALENCE; PROGNOSIS; RISK FACTORS;

EID: 67449100174     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080902902s29     Document Type: Conference Paper

References (9)

1. Li PKT, Szeto CC. Success of the peritoneal dialysis programme in Hong Kong. Nephrol Dial Transplant 2008; 23:1475-8.
2. Li PKT, Chow KM. The clinical and epidemiological aspects of vascular mortality in chronic peritoneal dialysis patients. Perit Dial Int 2005; 25(Suppl 3):S80-3.
3. Li PKT, Kwan BCK, Szeto CC, Ko GTC. Metabolic syndrome in peritoneal dialysis patients. Nephrol Dial Transplant Plus 2008; 4:206-14.
4. Kwan BC, Szeto CC, Chow KM, Leung CB, Li PKT. Metabolic syndrome and cardiovascular mortality in Chinese PD patients [Abstract]. Perit Dial Int 2008; 28(Suppl 4):S60.
5. Ramkumar N, Pappas LM, Beddhu S. Effect of body size and body composition on survival in peritoneal dialysis patients. Perit Dial Int 2005; 25:461-9.
6. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PKT. New onset hyperglycemia in non-diabetic Chinese patients started on peritoneal dialysis. Am J Kidney Dis 2007; 49: 524-32.
7. Wong TY, Szeto CC, Chow KM, Leung CB, Lam CWK, Li PKT. Rosiglitazone (RSG) reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients on peritoneal dialysis. Am J Kidney Dis 2005; 46:713-19.
8. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139: 105-12.
9. Johnson DW, Armstrong K, Campbell SB, Mudge DW, Hawley CM, Coombes JS, et al. Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) 2007; 12:391-8.